A Phase 1 interventional study of Dabigatran etexilate and Dabigatran etexilate in Cardiovascular Diseases and Kidney Failure, Chronic, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 21 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-04-07.
Sponsored by Boehringer Ingelheim · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The current study will allow the assessment of pharmacokinetics, pharmacodynamics, elimination rate and clearance of dabigatran etexilate during and following haemodialysis in ESRD patients.
5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.
This study's enrollment of 7 is below the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Capsule, oral
Drug: Dabigatran etexilate
Capsule, oral
Drug: Dabigatran etexilate
Capsule, oral
Drug: Dabigatran etexilate
150 mg capsule
75 mg capsule
110 mg capsule
Dialysis Clearance of Dabigatran
Dialysis clearance of dabigatran from blood (CLD,b) and dialysis clearance of dabigatran from plasma (CLD) were calculated and indicate how quickly dabigatran is cleared out from blood or plasma.
Time frame: 4 hours
Extent Cleared From Circulation (Plasma) During 1 Complete Cycle of Dialysis
Extent of dabigatran that is removed from blood during one complete 4-hour cycle of dialysis was computed by the difference of plasma concentration at the start and at the end of dialysis relative to the start concentration and is therefore measured as a percentage.
Time frame: 4 hours
Plasma Concentration Extraction Ratio
Plasma concentration extraction ratio was measured directly at the dialysis machine and computed as the difference of the predialysis plasma concentration and the postdialysis plasma concentration relative to the predialysis concentration on the percentage scale (minimum: 0 percent of extraction (worst), maximum: 100 percent of extraction).
Time frame: 4 hours
Area Under the Curve Exposure to Dabigatran During the First 8 Hours Post Dose (AUC0-8h)
Area under the concentration-time curve of total and free dabigatran in plasma over the time interval from 0 to 8 hours after the second and third administration of dabigatran.
Time frame: Days 2 and 3
Maximum Plasma Concentrations of Dabigatran (Cmax)
Maximum measured concentration of total and free dabigatran in plasma after the second and third administration of dabigatran.
Time frame: Days 2 and 3
Time to Maximum Plasma Concentration (Tmax)
Time to maximum plasma concentration of total and free dabigatran in plasma after the third administration of dabigatran.
Time frame: Day 3
Coagulation Parameters
Assessment of blood coagulation parameters 'activated partial thromboplastin time' (aPTT) and 'factor IIa inhibition' (anti-FIIa) measured with the diluted thrombin time assay. Time to the formation of a fibrin clot (coagulation) is measured in seconds.
Time frame: Day 3
Safety and Tolerability
Tolerability refers to the number of non-tolerable patients as assessed through the subjective examination of adverse events (AE). Safety refers to the number of patients with treatment emergent AEs. These numbers are presented on the overall Dabigatran treatment.
Time frame: 2 periods of 5 days each
Additional Safety Parameters
By study design abnormalities could be due to dialysis or Dabigatran.
Time frame: 2 periods of 5 days each
| Milestone | Dabigatran |
|---|---|
| Started | 7 |
| Completed | 7 |
| Not completed | 0 |
| Milestone | Dabigatran |
|---|---|
| Started | 7 |
| Completed | 7 |
| Not completed | 0 |
Dialysis clearance of dabigatran from blood (CLD,b) and dialysis clearance of dabigatran from plasma (CLD) were calculated and indicate how quickly dabigatran is cleared out from blood or plasma.
| mL/min | Dabigatran P1 | Dabigatran P2 |
|---|---|---|
| Total dabigatran clearance (CLD,b) from blood | 161 ± 5.01 | 241 ± 3.08 |
| Total dabigatran clearance (CLD) from plasma | 120 ± 5.09 | 183 ± 4.30 |
| Free dabigatran clearance (CLD,b) from blood | 167 ± 4.60 | 251 ± 2.17 |
| Free dabigatran clearance (CLD) from plasma | 124 ± 4.48 | 190 ± 3.68 |
Extent of dabigatran that is removed from blood during one complete 4-hour cycle of dialysis was computed by the difference of plasma concentration at the start and at the end of dialysis relative to the start concentration and is therefore measured as a percentage.
| Percentage | Dabigatran P1 | Dabigatran P2 |
|---|---|---|
| Total Dabigatran | 48.8 ± 10.9 | 59.3 ± 6.69 |
| Free Dabigatran | 49.7 ± 9.10 | 59.3 ± 6.13 |
Plasma concentration extraction ratio was measured directly at the dialysis machine and computed as the difference of the predialysis plasma concentration and the postdialysis plasma concentration relative to the predialysis concentration on the percentage scale (minimum: 0 percent of extraction (worst), maximum: 100 percent of extraction).
| Percentage | Dabigatran P1 | Dabigatran P2 |
|---|---|---|
| Total Dabigatran | 79.9 ± 9.01 | 61.4 ± 9.54 |
| Free Dabigatran | 82.6 ± 8.21 | 63.7 ± 8.60 |
Area under the concentration-time curve of total and free dabigatran in plasma over the time interval from 0 to 8 hours after the second and third administration of dabigatran.
| ng*hr/mL | Dabigatran P1 | Dabigatran P2 |
|---|---|---|
| Total Dabigatran on Day 2 | 1230 ± 57.1 | 1140 ± 39.4 |
| Total Dabigatran on Day 3 | 1280 ± 54.4 | 1180 ± 50.2 |
| Free Dabigatran on Day 2 | 907 ± 51.6 | 802 ± 44.1 |
| Free Dabigatran on Day 3 | 839 ± 41.3 | 752 ± 58.0 |
Maximum measured concentration of total and free dabigatran in plasma after the second and third administration of dabigatran.
| ng/mL | Dabigatran P1 | Dabigatran P2 |
|---|---|---|
| Total Dabigatran on Day 2 | 194 ± 53.1 | 171 ± 36.2 |
| Total Dabigatran on Day 3 | 176 ± 54.1 | 159 ± 50.2 |
| Free Dabigatran on Day 2 | 150 ± 47.3 | 126 ± 38.1 |
| Free Dabigatran on Day 3 | 119 ± 43.7 | 105 ± 57.3 |
Time to maximum plasma concentration of total and free dabigatran in plasma after the third administration of dabigatran.
| h | Dabigatran P1 | Dabigatran P2 |
|---|---|---|
| Total Dabigatran | 1.49 ± 38.4 | 2.13 ± 74.1 |
| Free Dabigatran | 1.35 ± 38.4 | 1.83 ± 27.3 |
Assessment of blood coagulation parameters 'activated partial thromboplastin time' (aPTT) and 'factor IIa inhibition' (anti-FIIa) measured with the diluted thrombin time assay. Time to the formation of a fibrin clot (coagulation) is measured in seconds.
| sec | Dabigatran P1 | Dabigatran P2 |
|---|---|---|
| Activated partial thromboplastin time (aPTT) | 46.91 ± 12.22 | 44.26 ± 10.98 |
| Factor IIa inhibition (anti-FIIa) | 43.27 ± 7.99 | 43.09 ± 5.38 |
Tolerability refers to the number of non-tolerable patients as assessed through the subjective examination of adverse events (AE). Safety refers to the number of patients with treatment emergent AEs. These numbers are presented on the overall Dabigatran treatment.
| Participants | Dabigatran |
|---|---|
| Treatment emergent adverse events | 2 |
| Assessment of tolerability by the investigator | 0 |
By study design abnormalities could be due to dialysis or Dabigatran.
| Participants | Dabigatran |
|---|---|
| Electrocardiogram (ECG) abnormalities | 0 |
| Vital sign abnormalities | 0 |
| Physical finding abnormalities | 0 |
| Laboratory abnormalities: Haematology | 0 |
| Laboratory abnormalities: Clinical chemistry | 0 |
Collected over 2 periods of 5 days each. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dabigatran | — | 0/7 (0%) | 2/7 (28.6%) |
| Event | Dabigatran |
|---|---|
| HeadacheNervous system disorders | 1/7 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/7 |
Treated set (TS) included all 7 subjects who were dispensed trial medication and were documented to have taken at least 1 dose of investigational treatment.
| Age, Continuous(Years) | Dabigatran |
|---|---|
| Mean | 38.3 ± 10.9 |
| Sex: Female, Male(Participants) | Dabigatran |
|---|---|
| Female | 0 |
| Male | 7 |
The record gives a start of Nov 2010 and a primary completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2012, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dabigatran